Cargando…

CAR-Based Therapy for Autoimmune Diseases: A Novel Powerful Option

The pervasive application of chimeric antigen receptor (CAR)-based cellular therapies in the treatment of oncological diseases has long been recognized. However, CAR T cells can target and eliminate autoreactive cells in autoimmune and immune-mediated diseases. By doing so, they can contribute to an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Műzes, Györgyi, Sipos, Ferenc
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10252902/ https://www.ncbi.nlm.nih.gov/pubmed/37296654 http://dx.doi.org/10.3390/cells12111534

Ejemplares similares

Mesenchymal Stem Cell-Derived Secretome: A Potential Therapeutic Option for Autoimmune and Immune-Mediated Inflammatory Diseases
por: Műzes, Györgyi, et al.
Publicado: (2022)

Issues and opportunities of stem cell therapy in autoimmune diseases
por: Műzes, Györgyi, et al.
Publicado: (2019)

Autoimmunity and Carcinogenesis: Their Relationship under the Umbrella of Autophagy
por: Műzes, Györgyi, et al.
Publicado: (2023)

Cancer Stem Cell Relationship with Pro-Tumoral Inflammatory Microenvironment
por: Sipos, Ferenc, et al.
Publicado: (2023)

Therapeutic aspects of c-MYC signaling in inflammatory and cancerous colonic diseases
por: Sipos, Ferenc, et al.
Publicado: (2016)

Disagreements in the therapeutic use of mesenchymal stem cell-derived secretome
por: Sipos, Ferenc, et al.
Publicado: (2022)

Colitis and Colorectal Carcinogenesis: The Focus on Isolated Lymphoid Follicles
por: Műzes, Györgyi, et al.
Publicado: (2022)

Cell-Free DNA in the Pathogenesis and Therapy of Non-Infectious Inflammations and Tumors
por: Műzes, Györgyi, et al.
Publicado: (2022)

Relation of the IGF/IGF1R system to autophagy in colitis and colorectal cancer
por: Sipos, Ferenc, et al.
Publicado: (2017)

Peripheral Blood Based Discrimination of Ulcerative Colitis and Crohn’s Disease from Non-IBD Colitis by Genome-Wide Gene Expression Profiling
por: Sipos, Ferenc, et al.
Publicado: (2011)

Association of Self-DNA Mediated TLR9-Related Gene, DNA Methyltransferase, and Cytokeratin Protein Expression Alterations in HT29-Cells to DNA Fragment Length and Methylation Status
por: Fűri, István, et al.
Publicado: (2013)

Survival of HT29 cancer cells is influenced by hepatocyte growth factor receptor inhibition through modulation of self-DNA-triggered TLR9-dependent autophagy response
por: Bohusné Barta, Bettina, et al.
Publicado: (2022)

Survival of HT29 Cancer Cells Is Affected by IGF1R Inhibition via Modulation of Self-DNA-Triggered TLR9 Signaling and the Autophagy Response
por: Sipos, Ferenc, et al.
Publicado: (2022)

Application of CAR-T Cell Therapy beyond Oncology: Autoimmune Diseases and Viral Infections
por: Zmievskaya, Ekaterina, et al.
Publicado: (2021)

CAR T Cells: A Snapshot on the Growing Options to Design a CAR
por: Holzinger, Astrid, et al.
Publicado: (2019)

CARs: a new approach for the treatment of autoimmune diseases
por: Sun, Yeting, et al.
Publicado: (2022)

Myofibroblast-Derived SFRP1 as Potential Inhibitor of Colorectal Carcinoma Field Effect
por: Valcz, Gábor, et al.
Publicado: (2014)

CAR T cells for treating autoimmune diseases
por: Blache, Ulrich, et al.
Publicado: (2023)

Antibody Therapies in Autoimmune Inflammatory Myopathies: Promising Treatment Options
por: Zeng, Rachel, et al.
Publicado: (2022)

Immunotherapy Deriving from CAR-T Cell Treatment in Autoimmune Diseases
por: Chen, Yuehong, et al.
Publicado: (2019)

Emerging Novel Combined CAR-T Cell Therapies
por: Nguyen, Anh, et al.
Publicado: (2022)

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
por: Pan, Kevin, et al.
Publicado: (2022)

Seatbelts in CAR therapy: How Safe Are CARS?
por: Minagawa, Kentaro, et al.
Publicado: (2015)

Altered Immune Regulation in Type 1 Diabetes
por: Zóka, András, et al.
Publicado: (2013)

Horses for Courses in the Era of CARs: Advancing CAR T and CAR NK Cell Therapies
por: Kulemzin, Sergey, et al.
Publicado: (2021)

Blinatumomab Prior to CAR-T Cell Therapy—A Treatment Option Worth Consideration for High Disease Burden
por: Marschollek, Paweł, et al.
Publicado: (2022)

The development of CAR design for tumor CAR-T cell therapy
por: Xu, Dandan, et al.
Publicado: (2018)

Engineering switchable and programmable universal CARs for CAR T therapy
por: Liu, Delong, et al.
Publicado: (2019)

CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies
por: Marofi, Faroogh, et al.
Publicado: (2021)

CARs and Drugs: Pharmacological Ways of Boosting CAR-T-Cell Therapy
por: Harrer, Dennis Christoph, et al.
Publicado: (2023)

Regulatory CAR-T cells in autoimmune diseases: Progress and current challenges
por: Riet, Tobias, et al.
Publicado: (2022)

The power of telemedicine to improve CAR-T cell therapy programs: lessons learned from COVID-19 pandemic
por: Canale, Filippo A., et al.
Publicado: (2023)

A review of renewable energy based power supply options for telecom towers
por: Deevela, Niranjan Rao, et al.
Publicado: (2023)

Treatment Equity in the Immunotherapy Era: Options for Patients with Both Autoimmune Disease and GU Cancers
por: Hui, Gavin, et al.
Publicado: (2022)

Novel antigens of CAR T cell therapy: New roads; old destination
por: Safarzadeh Kozani, Pooria, et al.
Publicado: (2021)

Target selection for CAR-T therapy
por: Wei, Jianshu, et al.
Publicado: (2019)

Gut microbiome and CAR-T therapy
por: Abid, Muhammad Bilal, et al.
Publicado: (2019)

The Application of Nanobody in CAR-T Therapy
por: Bao, Chaolemeng, et al.
Publicado: (2021)

Vitamin D Receptor Agonists: Suitable Candidates as Novel Therapeutic Options in Autoimmune Inflammatory Myopathy
por: Crescioli, Clara
Publicado: (2014)

Making CAR T Cells a Solid Option for Solid Tumors
por: Schmidts, Andrea, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_3r9skfqjn3tinirr26uat0glib